BetaGlue Therapeutics S.p.A.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
BetaGlue Therapeutics S.p.A. - overview
Established
2017
Location
Milan, -, Italy
Primary Industry
Medical Devices & Equipment
About
Based in Milan, Italy, and founded in 2017, BetaGlue Therapeutics S. p. A. operates as a clinical-stage oncology company that focuses on developing radiotherapeutic treatments for cancer.
In December 2024, BetaGlue Therapeutics S. p. A. raised EUR 6 million in venture funding from new investor ENEA Tech e Biomedical Foundation.
The company’s flagship product, YntraDose, represents a groundbreaking advancement in interventional oncology, offering a targeted and personalized approach to radiotherapy. BetaGlue Therapeutics addresses the limitations of existing radiotherapy methods, such as stereotactic body radiotherapy (SBRT) and proton beam radiotherapy (PBRT), which often struggle with challenges like internal organ movement and require significant investment in specialized equipment. The company will use the December 2024 funding to support its research and development in the field of life sciences.
Current Investors
Innogest, Panakes Partners, Kairos Partners
Primary Industry
Medical Devices & Equipment
Sub Industries
Oncology/Cancer Treatment, Surgical Devices, Medical Equipment Distributors
Website
www.betaglue.com
Verticals
HealthTech, Manufacturing
Company Stage
Series A
Total Amount Raised
Subscriber access only
BetaGlue Therapeutics S.p.A. - timeline of key events
BetaGlue Therapeutics S.p.A. - financials
| Fiscal Year Ended | Dec 31, 2013 | Dec 31, 2014 | Dec 31, 2015 | Dec 31, 2016 | Dec 31, 2017 | Dec 31, 2018 | Dec 31, 2019 | Dec 31, 2020 | Dec 31, 2021 | Dec 31, 2022 | Dec 31, 2023 | Dec 31, 2024 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue (USD) | - | - | - | - | - | - | - | - | - | - | - | - |
| % Revenue Growth (YoY) | - | - | - | - | - | - | - | - | - | - | - | - |
| EBITDA (USD) | (103,672) | (268,045) | (37,732) | (391,109) | (407,523) | (1,226,194) | (977,573) | (483,485) | (617,375) | - | - | - |
| Operating Income (USD) | (103,672) | (268,045) | (37,732) | (391,109) | (407,523) | (1,226,194) | (977,573) | (486,947) | (620,895) | - | - | - |
| Operating Margin | - | - | - | - | - | - | - | - | - | - | - | - |
| % EBITDA Margin | - | - | - | - | - | - | - | - | - | - | - | - |
| NET Income (USD) | (91,771) | (253,148) | (97,278) | (391,155) | (405,813) | (1,220,929) | (981,709) | (482,757) | (622,284) | - | - | - |
| % Net Margin | - | - | - | - | - | - | - | - | - | - | - | - |
BetaGlue Therapeutics S.p.A. - employee data
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.